Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Oncology studies lack full disclosure of industry payments
Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.
Key clinical point: Financial disclosure statements in published oncology studies are often incomplete.
Major finding: Among study authors involved in oncology trials, 32% did not fully disclose payments from trial sponsors.
Study details: A comparison of financial disclosure statements in published studies with information from the Open Payments database. The researchers looked at studies that supported U.S. oncology drug approvals from Jan. 1, 2016, to Aug. 31, 2017.
Disclosures: The researchers reported having no financial disclosures.
Citation:
Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738.